Biothera Release: Combination of Imprime PGG and Erbitux Doubles the Therapeutic Response in Colorectal Cancer Patients in Phase Ib/IIa Trial

Published: Jul 06, 2010

BARCELONA, Spain--(BUSINESS WIRE)--The combination of Biothera’s experimental drug Imprime PGG® and Erbitux® (cetuximab) doubled the historical overall response rate and the time to progression of second- and third-line metastatic colorectal cancer patients treated with Erbitux monotherapy. The data was released last weekend at the 13th World Congress on Gastrointestinal Cancer at the European Society for Medical Oncology (ESMO).

Back to news